147 Impact of sepsis and antibiotics on the microbiome 44. Seale JV, Hutchinson RA, Fleming PF et al. Does antibiotic choice for the treatment of suspected late-onset sepsis in premature infants determine the risk of developing necrotising enterocolitis? A systematic review. Early Hum Dev 2018; 123: 6–10. 45. Blaser M. Antibiotic overuse: Stop the killing of beneficial bacteria. Nature 2011; 476: 393–4. 46. Vincent J-L, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323–9. 47. Roager HM, Hansen LBS, Bahl MI et al. Colonic transit time is related to bacterial metabolism and mucosal turnover in the gut. Nat Microbiol 2016; 1: 16093. 48. Price R, MacLennan G, Glen J et al. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. BMJ 2014; 348: g2197. 49. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407–15. 50. de Smet AMGA, Kluytmans JAJW, Blok HEM et al. Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered group-randomised, crossover study. Lancet Infect Dis 2011; 11: 372–80. 51. Manzanares W, Lemieux M, Langlois PL et al. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit Care 2016; 19: 262. 52. Panigrahi P, Parida S, Nanda NC et al. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature 2017; 548: 407–12. 53. Moellering RC. Pharmacokinetics of vancomycin. J Antimicrob Chemoth 1984; 14 Suppl D: 43–52. 54. Nord CE, Brismar B, Kasholm-Tengve B et al. Effect of piperacillin/tazobactam treatment on human bowel microflora. J Antimicrob Chemoth 1993; 31 Suppl A: 61–5. 55. Kundrapu S, Sunkesula VCK, Jury LA et al. Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization? BMC Infect Dis 2016; 16: 159. 56. Kager L, Malmborg AS, Nord CE et al. The effect of piperacillin prophylaxis on the colonic microflora In patients undergoing colorectal surgery. Infection 1983; 11: 251–4. 57. Stiefel U, Pultz NJ, Helfand MS et al. Increased susceptibility to vancomycin-resistant Enterococcus intestinal colonization persists after completion of anti-anaerobic antibiotic treatment in mice. Infect Cont Hosp Ep 2004; 25: 373–9. 58. Paterson DL, Muto CA, Ndirangu M et al. Acquisition of rectal colonization by vancomycinresistant Enterococcus among intensive care unit patients treated with piperacillintazobactam versus those receiving cefepime-containing antibiotic regimens. Antimicrob Agents Chemoth 2008; 52: 465–9. 59. Bächer K, Schaeffer M, Lode H et al. Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Ch 1992; 30: 365–75. 60. Kemmerich B, Warns H, Lode H et al. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother 1983; 24: 333–8. 61. Knothe H, Dette GA, Shah PM. Impact of injectable cephalosporins on the gastrointestinal microflora: observations in healthy volunteers and hospitalized patients. Infection 1985; 13 Suppl 1: S129-133. 62. Flokas ME, Karageorgos SA, Detsis M et al. Vancomycin-resistant enterococci colonisation, risk factors and risk for infection among hospitalised paediatric patients: a systematic review and meta-analysis. Int J Antimicrob Ag 2017; 49: 565–72. 63. Rice LB, Hutton-Thomas R, Lakticova V et al. Beta-lactam antibiotics and gastrointestinal colonization with vancomycin-resistant enterococci. J Infect Dis 2004; 189: 1113–8. 6
RkJQdWJsaXNoZXIy MTk4NDMw